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MOO E P OBLEMS
The number of drugs approved by the US Food and Drug Administration (FDA) per billion US dollars spent on research and development (R&D) has halved roughly every 9 years since 1950 -seemingly the opposite of Moore's law (Gordon Moore, co-founder of technology company Intel, observed that the number of transistors that can be placed, inexpensively, on an integrated circuit doubles every 18-24 months) 2 . In an e ort to defy 'Eroom's law', organizations have been forced to search for ways to boost returns on investment.
ST AIGHT PATHS OF OLD
Historically, life-sciences partnerships were linear and closed in nature. The conception, development and delivery of therapies was handled separately -the involvement of one partner ending as that of another began.
This arrangement had its advantages. Risk and reward increased as the drug moved down the chain. But the lack of dialogue with the wider community could often result in costly duplications of e ort.
A G OWING MOVEMENT
In response to the limitations of the closed model of innovation, a growing number of organizations have come together over the past two decades to share ideas, data and tools with each other, and often with the wider community.
UNMET NEEDS
A conventional closed model of innovation is unsuitable for some medical needs, such as the development of antimalarials or Ebola vaccines.
INC EASING INFO MATION
As researchers better understand the biological complexity of targeted diseases, and the technological complexity of drug discovery and the size of data sets increase, organizations are becoming more reliant on outside expertise.
SQUEEZED MA GINS
Increasing R&D costs and competition from drugs that are no longer covered by patents have squeezed the margins of the conventional linear innovation model.
BASIC ESEA CH DISCOVE Y & DEVELOPMENT T EATMENT
Average pre-tax cost per approved drug, including cost of failures 1 US$2. 6 billion 
DEG EES OF OPENNESS CASE STUDIES
OPEN ACCESS
Open access was a major shake up to the conventional publishing model. Literature is digital, online, free at the point of use and usually free to reproduce in some form.
OPEN SCIENCE
Open science is the practice of science such that others can contribute. Lab notes are freely available, and the research and its underlying methods can be shared.
OPEN DATA
The 
PA TICIPATION ACCESS SCOPE OPEN SOU CE MALA IA
The project takes promising public domain compounds and re nes them for clinical trials. Anyone can contribute and all experimental data are shared in near-real time. E-mails are discouraged, with contributors instead urged to communicate on public discussion boards. 
ST UCTU AL GENOMICS CONSO TIUM
The consortium is a public-private partnership that aims to catalyse drug-discovery e orts by determining the structure of potential drug targets. The structures are then released to the public, but no data are made available before then. 
